Telehealth vs In-Person Evaluation of Addiction Treatment After Visiting the Emergency Department

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of California, Davis

About this trial

Main study objective: compare long-term buprenorphine treatment outcomes for patients who start buprenorphine for opioid use disorder (OUD) in the emergency department and are then referred to get outpatient buprenorphine treatment either via telehealth or at an in-person clinic.

Researchers will:

Compare rates of establishing outpatient OUD treatment, how long patients stay on buprenorphine, and patients' experience with care to determine whether patient experiences and outcomes are better for patients referred to telehealth treatment versus patients patients referred to in-person treatment after they leave the emergency department.

Participants will:

Be recruited from 3 different hospital emergency departments.

Answer questionnaires at baseline and then 1, 3, 6, and 9 months after their initial emergency department visit.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult patients who present to the emergency department and receive buprenorphine (either administered or prescribed) to treat OUD

do not have an established outpatient clinic where they will get buprenorphine when they leave the emergency department

Disqualifiers

inability to give consent

patients living in institutions (e.g., nursing homes, prisons)

unable to complete questionnaires in either English or Spanish

Trial design

Design model

Parallel

Treatments tested in this trial

  • referral to telehealth treatment

    Other intervention

    the intervention tested will be referral to get outpatient treatment via telehealth. Participants in the telehealth arm will receive the intervention.

  • referral to in person treatment

    Other intervention

    participants in the in person arm will be referred to in person OUD treatment after they leave the ED

Treatment groups

528 Participants
are divided into 2 treatment groups
Group A: in personActive comparator 1 intervention
Group B: telehealthExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

buprenorphine retention

cumulative days with an active buprenorphine prescription

Time frame
6 months

Secondary outcomes

1

buprenorphine retention

cumulative days with an active buprenorphine prescription

Time frame
3 months, 9 months
2

buprenorphine retention (binary)

active buprenorphine prescription with no gap in coverage \>7 days

Time frame
3, 6, 9 months
3

drug overdose death

death related to overdose

Time frame
1, 3, 6, 9 months
4

past 30-day opioid use

patient-reported number of days patient used opioids (illicit opioids or prescription opioids for non-medical reasons) during past 30 days

Time frame
1, 3, 6, 9 months

Other outcomes

1

health care utilization

emergency department visits and/or hospital admissions

Time frame
1, 3, 6, 9 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of California, Davis

Lead sponsor

Patient-Centered Outcomes Research Institute

Collaborator